Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology.

Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM.

Sci Transl Med. 2012 Sep 5;4(150):150ra122. doi: 10.1126/scitranslmed.3004291.

2.

Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model.

Liao F, Zhang TJ, Mahan TE, Jiang H, Holtzman DM.

Brain Behav Immun. 2015 Jul;47:163-71. doi: 10.1016/j.bbi.2014.09.005. Epub 2014 Sep 16.

3.

Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM.

Science. 2009 Nov 13;326(5955):1005-7. doi: 10.1126/science.1180962. Epub 2009 Sep 24.

4.

Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation.

Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ.

J Neurosci. 2011 Nov 2;31(44):15861-9. doi: 10.1523/JNEUROSCI.3272-11.2011.

5.

Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis.

Lucey BP, Bateman RJ.

Neurobiol Aging. 2014 Sep;35 Suppl 2:S29-34. doi: 10.1016/j.neurobiolaging.2014.03.035. Epub 2014 May 15. Review.

6.

Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease.

Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM.

J Exp Med. 2014 Dec 15;211(13):2487-96. doi: 10.1084/jem.20141788. Epub 2014 Nov 24. Erratum in: J Exp Med. 2015 Jan 12;212(1):121.

7.

The nexus of Aβ, aging, and sleep.

Gerstner JR, Perron IJ, Pack AI.

Sci Transl Med. 2012 Sep 5;4(150):150fs34. doi: 10.1126/scitranslmed.3004815.

PMID:
22956197
8.

The sleep-wake cycle and Alzheimer's disease: what do we know?

Lim MM, Gerstner JR, Holtzman DM.

Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33. Review.

9.

Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.

Colby-Milley J, Cavanagh C, Jego S, Breitner JC, Quirion R, Adamantidis A.

PLoS One. 2015 Jun 15;10(6):e0130177. doi: 10.1371/journal.pone.0130177. eCollection 2015.

10.

Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer's disease.

Duncan MJ, Smith JT, Franklin KM, Beckett TL, Murphy MP, St Clair DK, Donohue KD, Striz M, O'Hara BF.

Exp Neurol. 2012 Aug;236(2):249-58. doi: 10.1016/j.expneurol.2012.05.011. Epub 2012 May 22.

PMID:
22634208
11.

Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.

Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY, Kim YS, Lee J, Mook-Jung I.

J Alzheimers Dis. 2012;29(3):615-28. doi: 10.3233/JAD-2011-111778.

PMID:
22269161
12.

In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.

Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM.

J Neurosci. 2003 Oct 1;23(26):8844-53.

13.

Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.

Zhao G, Liu HL, Zhang H, Tong XJ.

Neuroscience. 2015 Jul 9;298:357-66. doi: 10.1016/j.neuroscience.2015.04.038. Epub 2015 Apr 23.

PMID:
25917310
14.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
15.

Neuronal activity regulates the regional vulnerability to amyloid-β deposition.

Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM.

Nat Neurosci. 2011 Jun;14(6):750-6. doi: 10.1038/nn.2801. Epub 2011 May 1.

16.

Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.

Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ.

Arch Neurol. 2012 Jan;69(1):51-8. doi: 10.1001/archneurol.2011.235. Epub 2011 Sep 12.

17.

Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.

Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ.

PLoS One. 2014 Mar 19;9(3):e89998. doi: 10.1371/journal.pone.0089998. eCollection 2014.

18.

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA.

Neurodegener Dis. 2012;10(1-4):265-70. doi: 10.1159/000335913. Epub 2012 Feb 16.

19.
20.

Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H.

J Alzheimers Dis. 2009;17(3):681-97. doi: 10.3233/JAD-2009-1071. Erratum in: J Alzheimers Dis. 2009 Nov;18(3):727. Wang, Lilly [corrected to Wang, Li]..

Supplemental Content

Support Center